← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Torrey Pines Inst For Molecular Studies
San Diego, CA
$73,119,867
Total funding
77
Grants
Funding over time
peak $6.1M · FY2005–20$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$73,119,867 · 77
By mechanism
R01$55,386,854 · 39
R21$8,950,074 · 19
P41$2,923,133 · 2
P01$2,550,606 · 6
N01$943,410 · 1
R03$662,791 · 4
Investigators at Torrey Pines Inst For Molecular Studies
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
COMBINATORIAL APPROACHES TO TREAT NEOPLASTIC DISEASES$1,753,167
P01 · FY2001 · CA
COMBINATORIAL APPROACHES TO TREAT NEOPLASTIC DISEASES$1,506,546
P01 · FY2002 · CA
COMBINATORIAL APPROACHES TO TREAT NEOPLASTIC DISEASES$1,426,535
P01 · FY2000 · CA
Novel RORgamma antagonists for inflammation and autoimmune disease$751,968
R01 · FY2014 · AI
NPQ/Spexin the Endogenous Ligand for the Galanin Receptor 3$742,361
R01 · FY2016 · DA
NPQ/Spexin the Endogenous Ligand for the Galanin Receptor 3$714,012
R01 · FY2017 · DA
Mixed NOP/mu Compounds and the Involvement of Their Receptors in Analgesia$652,346
R01 · FY2017 · DA
SELECTING ENV TRIMERS IN HIV-VLP VACCINE PRESENTATIONS$628,213
R01 · FY2006 · AI
Therapeutic Opportunities of Targeting Tissue Factor Signaling in Obesity$619,081
R01 · FY2011 · HL
Therapeutic Opportunities of Targeting Tissue Factor Signaling in Obesity$608,277
R01 · FY2012 · HL
Novel RORgamma antagonists for inflammation and autoimmune disease$590,333
R01 · FY2016 · AI
Novel RORgamma antagonists for inflammation and autoimmune disease$584,371
R01 · FY2017 · AI
Novel RORgamma antagonists for inflammation and autoimmune disease$580,731
R01 · FY2015 · AI
Therapeutic Opportunities of Targeting Tissue Factor Signaling in Obesity$575,680
R01 · FY2013 · HL
Pure and Authentic HIV-1 Env Immunogens$562,213
R01 · FY2012 · AI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia.$516,146
R01 · FY2014 · DA
High throughput in vivo screening: translational generation of novel analgesics$511,211
R01 · FY2013 · DA
New probes for matrix metalloproteinase 13$503,149
R01 · FY2013 · AR
High throughput in vivo screening: translational generation of novel analgesics$501,681
R01 · FY2012 · DA
Novel RORgamma antagonists for inflammation and autoimmune disease$489,026
R01 · FY2018 · AI